Company intelligence / Profile preview
Anaveon
Basel, Basel-Stadt, Switzerlandanaveon.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Anaveon's lead compound ANV419 has demonstrated the ability to deliver high-dose IL‑2 with a favorable safety and tolerability profile in patients with advanced solid tumors. As of March 2023, data from a Phase I study showed good safety and promising immunological activity. ANV419 has progressed into multiple Phase II studies targeting various cancer indications. Follow-on compounds such as ANV600 and ANV700 are advancing through preclinical and early clinical development, focusing on novel mechanisms to enhance anti-tumor immunity or reverse T-cell exhaustion.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cytokine-based biologics (including IL-2/anti–IL-2 antibody fusion proteins)Protein engineeringSelective cytokine receptor agonistsBispecifics (e.g., PD‑1 targeted therapeutics)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Anaveon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anaveon.